Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Download All
In this this dynamic program on the optimal treatment of patients with relapsed or refractory HER2-positive advanced breast cancer, renowned breast cancer experts review and discuss key clinical data and patient case studies and look ahead at promising agents that may soon change practice.
Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD
person default
Cristina Saura, MD, PhD

On-Demand Webcast

In this interactive, on-demand Webcast, experts share recent developments in the care of patients with HER2-positive metastatic breast cancer, including novel therapeutic agents and strategies utilizing new antibody–drug conjugates and tyrosine kinase inhibitors after failure of standard-of-care treatments.

Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD person default Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue